At close: January 6 at 4:00:00 PM EST
Breakdown
TTM
10/31/2024
10/31/2023
10/31/2022
10/31/2021
Operating Expense
62,297.0000
62,297.0000
26,060.0000
19,427.0000
15,870.0000
Operating Income
-62,297.0000
-62,297.0000
-26,060.0000
-19,427.0000
-15,870.0000
Net Non Operating Interest Income Expense
7,615.0000
7,615.0000
-3,836.0000
-1,294.0000
-4,999.0000
Other Income Expense
-479.0000
-479.0000
-70,004.0000
-3,719.0000
-2,572.0000
Pretax Income
-55,161.0000
-55,161.0000
-99,900.0000
-24,440.0000
-23,441.0000
Tax Provision
-19.0000
-19.0000
17.0000
22.0000
--
Net Income Common Stockholders
-55,142.0000
-55,142.0000
-104,739.0000
-29,024.0000
-22,250.0000
Diluted NI Available to Com Stockholders
-55,142.0000
-55,142.0000
-104,739.0000
-29,024.0000
-22,250.0000
Total Operating Income as Reported
-62,297.0000
-62,297.0000
-26,060.0000
-19,427.0000
-15,870.0000
Total Expenses
62,297.0000
62,297.0000
26,060.0000
19,427.0000
15,870.0000
Net Income from Continuing & Discontinued Operation
-55,142.0000
-55,142.0000
-99,917.0000
-24,462.0000
-23,441.0000
Normalized Income
-54,776.1098
-54,776.1098
-91,719.2000
-22,206.2397
-20,988.0000
Interest Income
10,413.0000
10,413.0000
1,117.0000
129.0000
25.0000
Interest Expense
2,798.0000
2,798.0000
4,953.0000
1,423.0000
5,024.0000
Net Interest Income
7,615.0000
7,615.0000
-3,836.0000
-1,294.0000
-4,999.0000
EBIT
-52,363.0000
-52,363.0000
-94,947.0000
-23,017.0000
-18,417.0000
EBITDA
-52,040.0000
-52,040.0000
-94,772.0000
-22,779.0000
-18,145.0000
Reconciled Depreciation
323.0000
323.0000
175.0000
238.0000
272.0000
Net Income from Continuing Operation Net Minority Interest
-55,142.0000
-55,142.0000
-99,917.0000
-24,462.0000
-23,441.0000
Total Unusual Items Excluding Goodwill
-366.0000
-366.0000
-13,663.0000
-3,057.0000
-2,453.0000
Total Unusual Items
-366.0000
-366.0000
-13,663.0000
-3,057.0000
-2,453.0000
Normalized EBITDA
-51,674.0000
-51,674.0000
-81,109.0000
-19,722.0000
-15,692.0000
Tax Rate for Calcs
0.0000
0.0000
0.0004
0.0003
--
Tax Effect of Unusual Items
-0.1098
-0.1098
-5,465.2000
-801.2397
--
-
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
SCNI Scinai Immunotherapeutics Ltd.
3.7700
+4.72%
IMCR Immunocore Holdings plc
29.87
+0.03%
RGNX REGENXBIO Inc.
8.19
+5.41%
CTMX CytomX Therapeutics, Inc.
1.1400
+0.88%
FDMT 4D Molecular Therapeutics, Inc.
6.35
+7.08%
PALI Palisade Bio, Inc.
2.2000
+15.79%
QNRX Quoin Pharmaceuticals, Ltd.
0.6690
-4.47%
VRAX Virax Biolabs Group Limited
3.1100
+27.98%
ZYME Zymeworks Inc.
14.46
-3.66%
ATOS Atossa Therapeutics, Inc.
0.9603
-4.92%